|
MechanismSARS-CoV-2 S protein modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismSARS-CoV-2 S protein modulators |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismIL1RAP inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
100 Clinical Results associated with Beijing Danxu Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with Beijing Danxu Biopharmaceutical Co., Ltd.
100 Deals associated with Beijing Danxu Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with Beijing Danxu Biopharmaceutical Co., Ltd.